Lanyun Yan

Dr. Lanyun Yan


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2021 in Brain Research Bulletin
Verified
Journal Article
Closed access
PZPinhuan Zhu
Pinhuan Zhu
XDXin Dong
Xin Dong
HXHuan Xu
Huan Xu
QWQi Wan
Qi Wan
QGQiqi Guo
Qiqi Guo
LYLanyun Yan
Lanyun Yan

27 July 2024 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
WZWeiyun Zhang
Weiyun Zhang
FWFen Wan
Fen Wan
LDLihui Duan
Lihui Duan
WTWen Tao
Wen Tao
JWJun Wang
Jun Wang
LYLanyun Yan
Lanyun Yan

14 February 2024 in European Journal of Neurology
Verified
Journal Article
Open access
WZWeiyun Zhang
Weiyun Zhang
WTWen Tao
Wen Tao
JWJun Wang
Jun Wang
PNPing Nie
Ping Nie
LDLihui Duan
Lihui Duan
LYLanyun Yan
Lanyun Yan
Background and purpose: Clinical symptoms and laboratory indices for acute inflammatory demyelinating polyneuropathy (AIDP), a variant of Guillain−Barré syndrome, and acute‐onset chronic inflammatory demyelinating polyneuropathy (A‐CIDP) were analyzed to identify factors that could contribute to early differential diagnosis.Methods: A retrospective chart review was performed on 44 AIDP and 44 A‐CIDP patients looking for any demographic characteristics, clinical manifestations or laboratory parameters that might differentiate AIDP from acutely presenting CIDP.Results: In Guillain−Barré syndrome patients (N = 63), 69.84% (N = 44) were classified as having AIDP, 19.05% (N = 12) were found to have acute motor axonal neuropathy, 6.35% (N = 4) were found to have acute motor and sensory axonal neuropathy, and 4.76% (N = 3) were found to have Miller Fisher syndrome. Serum uric acid (UA) was higher in A‐CIDP patients (329.55 ± 72.23 μmol/L) than in AIDP patients (221.08 ± 71.32 μmol/L) (p = 0.000). Receiver operating characteristic analyses indicated that the optimal UA cutoff was 283.50 μmol/L. Above this level, patients were more likely to present A‐CIDP than AIDP (specificity 81.80%, sensitivity 81.80%). During the follow‐up process, serum samples were effectively collected from 19 AIDP patients during the rehabilitation phase and 28 A‐CIDP patients during the remission stage, and it was found that UA levels were significantly increased in A‐CIDP (remission) (298.9 ± 90.39 μmol/L) compared with AIDP (rehabilitation) (220.1 ± 108.2 μmol/L, p = 0.009).Conclusion: These results suggest that serum UA level can help to differentiate AIDP from A‐CIDP with high specificity and sensitivity, which is helpful for early diagnosis and guidance of treatment.